Clinical Trials Logo

Clinical Trial Summary

To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various reasons.


Clinical Trial Description

Objectives: To describe and evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg in patients undergoing a full colonoscopy for various reasons. Primary end-point(s): To evaluate the mucosal staining efficacy of Methylene Blue MMX® tablets after total oral doses of 150 or 200 mg. Secondary end-point(s): Bowel cleansing quality evaluated according to the validated Boston Bowel Preparation Scale (BBPS) after intake of 150 or 200 mg of Methylene Blue MMX® tablets during the intake of the bowel cleansing preparation. To collect data about safety and tolerability of Methylene Blue MMX® tablets after administration of single oral doses of 150 or 200 mg. Methodology: Open label, staining efficacy exploratory study. ;


Study Design


Related Conditions & MeSH terms

  • Colon Staining in Preparation for Colonoscopy

NCT number NCT03287219
Study type Interventional
Source Cosmo Pharmaceuticals NV
Contact
Status Completed
Phase Phase 2
Start date May 2, 2011
Completion date January 16, 2012